GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0052547111 | Esophagus | ESCC | regulation of peptidase activity | 275/8552 | 461/18723 | 7.54e-10 | 1.88e-08 | 275 |
GO:0052548111 | Esophagus | ESCC | regulation of endopeptidase activity | 253/8552 | 432/18723 | 3.68e-08 | 6.78e-07 | 253 |
GO:0045861111 | Esophagus | ESCC | negative regulation of proteolysis | 195/8552 | 351/18723 | 1.13e-04 | 7.85e-04 | 195 |
GO:0051346110 | Esophagus | ESCC | negative regulation of hydrolase activity | 208/8552 | 379/18723 | 1.76e-04 | 1.14e-03 | 208 |
GO:001046620 | Esophagus | ESCC | negative regulation of peptidase activity | 140/8552 | 262/18723 | 6.73e-03 | 2.46e-02 | 140 |
GO:001095119 | Esophagus | ESCC | negative regulation of endopeptidase activity | 135/8552 | 252/18723 | 6.86e-03 | 2.51e-02 | 135 |
GO:005254722 | Liver | HCC | regulation of peptidase activity | 247/7958 | 461/18723 | 8.28e-07 | 1.27e-05 | 247 |
GO:005254822 | Liver | HCC | regulation of endopeptidase activity | 230/7958 | 432/18723 | 3.58e-06 | 4.68e-05 | 230 |
GO:004586122 | Liver | HCC | negative regulation of proteolysis | 186/7958 | 351/18723 | 4.19e-05 | 4.11e-04 | 186 |
GO:005134622 | Liver | HCC | negative regulation of hydrolase activity | 195/7958 | 379/18723 | 2.44e-04 | 1.82e-03 | 195 |
GO:001095121 | Liver | HCC | negative regulation of endopeptidase activity | 129/7958 | 252/18723 | 3.17e-03 | 1.47e-02 | 129 |
GO:001046621 | Liver | HCC | negative regulation of peptidase activity | 132/7958 | 262/18723 | 5.82e-03 | 2.42e-02 | 132 |
GO:005254719 | Prostate | Tumor | regulation of peptidase activity | 137/3246 | 461/18723 | 2.48e-11 | 1.71e-09 | 137 |
GO:005254819 | Prostate | Tumor | regulation of endopeptidase activity | 126/3246 | 432/18723 | 5.86e-10 | 3.01e-08 | 126 |
GO:004586119 | Prostate | Tumor | negative regulation of proteolysis | 102/3246 | 351/18723 | 3.09e-08 | 9.94e-07 | 102 |
GO:005134617 | Prostate | Tumor | negative regulation of hydrolase activity | 97/3246 | 379/18723 | 2.87e-05 | 3.46e-04 | 97 |
GO:001095116 | Prostate | Tumor | negative regulation of endopeptidase activity | 68/3246 | 252/18723 | 7.91e-05 | 8.19e-04 | 68 |
GO:001046617 | Prostate | Tumor | negative regulation of peptidase activity | 70/3246 | 262/18723 | 8.76e-05 | 8.66e-04 | 70 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CST1 | SNV | Missense_Mutation | | c.295N>T | p.Pro99Ser | p.P99S | P01037 | protein_coding | tolerated(0.2) | benign(0.02) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CST1 | SNV | Missense_Mutation | | c.114N>A | p.Asp38Glu | p.D38E | P01037 | protein_coding | tolerated(0.08) | possibly_damaging(0.64) | TCGA-AR-A251-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
CST1 | SNV | Missense_Mutation | rs367602743 | c.370G>A | p.Glu124Lys | p.E124K | P01037 | protein_coding | tolerated(0.39) | probably_damaging(0.973) | TCGA-E2-A10C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
CST1 | insertion | In_Frame_Ins | novel | c.70_71insTTCATGATCTAATGCTCAGATTCATTCAGCTTTCCCTGG | p.Lys24delinsIleHisAspLeuMetLeuArgPheIleGlnLeuSerLeuGlu | p.K24delinsIHDLMLRFIQLSLE | P01037 | protein_coding | | | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CST1 | SNV | Missense_Mutation | | c.181N>C | p.Asp61His | p.D61H | P01037 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
CST1 | SNV | Missense_Mutation | novel | c.252N>A | p.Phe84Leu | p.F84L | P01037 | protein_coding | tolerated(0.16) | benign(0.3) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
CST1 | SNV | Missense_Mutation | rs768059525 | c.205C>T | p.Arg69Trp | p.R69W | P01037 | protein_coding | tolerated(0.06) | benign(0.117) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CST1 | SNV | Missense_Mutation | | c.5C>T | p.Ala2Val | p.A2V | P01037 | protein_coding | deleterious(0.02) | possibly_damaging(0.855) | TCGA-A5-A0GP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CST1 | SNV | Missense_Mutation | rs746147492 | c.256N>A | p.Asp86Asn | p.D86N | P01037 | protein_coding | tolerated(0.13) | possibly_damaging(0.52) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CST1 | SNV | Missense_Mutation | rs201877331 | c.196C>T | p.Arg66Cys | p.R66C | P01037 | protein_coding | deleterious(0.03) | possibly_damaging(0.613) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |